

Ribociclib MONALEESA-2

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Ribociclib MONALEESA-2

### FINAL SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Therapeutic Indication: Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET  
 Experimental Arm: Ribociclib + Letrozole  
 Control Arm: Letrozole + placebo

